A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation

Conclusions. Apixaban is the most cost-effective therapy for stroke prevention in patients with new-onset NVAF without contraindications to OAC. Uncertainty around this conclusion exists, highlighting the need for further research.

http://mdm.sagepub.com/cgi/content/abstract/36/3/366?rss=1

Source: Medical Decision Making - February 29, 2016 Category: Health Management Authors: Micieli, A., Wijeysundera, H. C., Qiu, F., Atzema, C. L., Singh, S. M. Tags: Original Articles Source Type: research